Cargando…

Candesartan cilexetil in the treatment of chronic heart failure

The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzym...

Descripción completa

Detalles Bibliográficos
Autores principales: Baguet, Jean-Philippe, Barone-Rochette, Gilles, Neuder, Yannick
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672439/
https://www.ncbi.nlm.nih.gov/pubmed/19436650
_version_ 1782166536675393536
author Baguet, Jean-Philippe
Barone-Rochette, Gilles
Neuder, Yannick
author_facet Baguet, Jean-Philippe
Barone-Rochette, Gilles
Neuder, Yannick
author_sort Baguet, Jean-Philippe
collection PubMed
description The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of course that they are not contraindicated. However, angiotensin II receptor blockers (ARBs) can also be a beneficial treatment option. Candesartan is a particular ARB, characterized by a strong binding affinity to the angiotensin II type 1 receptor and slow dissociation. The benefits of candesartan have been demonstrated by the CHARM programme, which showed that candesartan significantly reduces the incidence of cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function, when added to standard therapies or as an alternative to ACE inhibitors when these are poorly tolerated. Furthermore, candesartan can protect against myocardial infarction, atrial fibrillation and diabetes. Tolerance to candesartan is good, but blood pressure and serum potassium and creatinine levels must be monitored.
format Text
id pubmed-2672439
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26724392009-08-08 Candesartan cilexetil in the treatment of chronic heart failure Baguet, Jean-Philippe Barone-Rochette, Gilles Neuder, Yannick Vasc Health Risk Manag Review The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of course that they are not contraindicated. However, angiotensin II receptor blockers (ARBs) can also be a beneficial treatment option. Candesartan is a particular ARB, characterized by a strong binding affinity to the angiotensin II type 1 receptor and slow dissociation. The benefits of candesartan have been demonstrated by the CHARM programme, which showed that candesartan significantly reduces the incidence of cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function, when added to standard therapies or as an alternative to ACE inhibitors when these are poorly tolerated. Furthermore, candesartan can protect against myocardial infarction, atrial fibrillation and diabetes. Tolerance to candesartan is good, but blood pressure and serum potassium and creatinine levels must be monitored. Dove Medical Press 2009 2009-04-08 /pmc/articles/PMC2672439/ /pubmed/19436650 Text en © 2009 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Baguet, Jean-Philippe
Barone-Rochette, Gilles
Neuder, Yannick
Candesartan cilexetil in the treatment of chronic heart failure
title Candesartan cilexetil in the treatment of chronic heart failure
title_full Candesartan cilexetil in the treatment of chronic heart failure
title_fullStr Candesartan cilexetil in the treatment of chronic heart failure
title_full_unstemmed Candesartan cilexetil in the treatment of chronic heart failure
title_short Candesartan cilexetil in the treatment of chronic heart failure
title_sort candesartan cilexetil in the treatment of chronic heart failure
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672439/
https://www.ncbi.nlm.nih.gov/pubmed/19436650
work_keys_str_mv AT baguetjeanphilippe candesartancilexetilinthetreatmentofchronicheartfailure
AT baronerochettegilles candesartancilexetilinthetreatmentofchronicheartfailure
AT neuderyannick candesartancilexetilinthetreatmentofchronicheartfailure